Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase

被引：96

作者：

Jiang, Jian-kang ^{[1
]}

Boxer, Matthew B. ^{[1
]}

Vander Heiden, Matthew G. ^{[2
,3
,4
]}

Shen, Min ^{[1
]}

Skoumbourdis, Amanda P. ^{[1
]}

Southall, Noel ^{[1
]}

Veith, Henrike ^{[1
]}

Leister, William ^{[1
]}

Austin, Christopher P. ^{[1
]}

Park, Hee Won ^{[5
,6
]}

Inglese, James ^{[1
]}

Cantley, Lewis C. ^{[3
,7
]}

Auld, Douglas S. ^{[1
]}

Thomas, Craig J. ^{[1
]}

机构：

[1] NHGRI, Chem Genom Ctr, NIH, Rockville, MD 20850 USA

[2] MIT, Robert Koch Inst, Cambridge, MA 02139 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA

[5] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L5, Canada

[6] Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada

[7] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 11期

基金：

美国国家卫生研究院; 英国惠康基金;

关键词：

Warburg effect; Pyruvate kinase; Cellular metabolism; Anti-cancer strategies; Small molecule activators; CANCER CELLS; M-GENE; GROWTH; RAT; IDENTIFICATION; METABOLISM; INHIBITORS; ISOZYMES; HALIDES; M2-PK;

D O I：

10.1016/j.bmcl.2010.04.015

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Cancer cells have distinct metabolic needs that are different from normal cells and can be exploited for development of anti-cancer therapeutics. Activation of the tumor specific M2 form of pyruvate kinase (PKM2) is a potential strategy for returning cancer cells to a metabolic state characteristic of normal cells. Here, we describe activators of PKM2 based upon a substituted thieno[3,2-b]pyrrole[3,2-d]pyridazinone scaffold. The synthesis of these agents, structure-activity relationships, analysis of activity at related targets (PKM1, PKR and PKL) and examination of aqueous solubility are investigated. These agents represent the second reported chemotype for activation of PKM2. Published by Elsevier Ltd.

引用

页码：3387 / 3393

页数：7

共 50 条

[31] Synthesis and Preliminary Cytotoxicity Evaluation of New Diarylamides and Diarylureas Possessing 2,3-Dihydropyrrolo[3,2-b]quinoline Scaffold
Kim, Hyun-Jin
El-Gamal, Mohammed I.
Lee, Yong Sup
Oh, Chang-Hyun
BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2013, 34 (08) : 2480 - 2486
[32] A NOVEL ONE-STEP SYNTHESIS OF BENZO[b]FURO[3,2-b]PYRIDINES HAVING AN AMINO GROUP AT THE 4-POSITION FROM BENZO[b]FURO[3,2-d][1,3]OXAZINE
Tabuchi, Yukako
Kakumoto, Yusa
Uchimoto, Hitomi
Kawasaki, Ikuo
Ohishi, Yoshitaka
Nishide, Kiyoharu
HETEROCYCLES, 2013, 87 (01) : 177 - 191
[33] Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform
Ning, Xianling
Qi, Hailong
Li, Ridong
Jin, Yan
McNutt, Michael A.
Yin, Yuxin
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2017, 33 (01) : 126 - 129
[34] Efficient New Synthesis of N-Arylbenzo[b]furo[3,2-d]pyrimidin-4-amines and Their Benzo[b]thieno[3,2-d]pyrimidin-4-amine Analogues via a Microwave-Assisted Dimroth Rearrangement
Loidreau, Yvonnick
Dubouilh-Benard, Carole
Marchand, Pascal
Nourrisson, Marie-Renee
Duflos, Muriel
Buquet, Catherine
Corbiere, Cecile
Besson, Thierry
JOURNAL OF HETEROCYCLIC CHEMISTRY, 2013, 50 (05) : 1187 - 1197
[35] Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors
Stevens, Kirk L.
Alligood, Krystal J.
Alberti, Jennifer G. Badiang
Caferro, Thomas R.
Chamberlain, Stanley D.
Dickerson, Scott H.
Dickson, Hamilton D.
Emerson, Holly K.
Griffin, Robert J.
Hubbard, Robert D.
Keith, Barry R.
Mullin, Robert J.
Petrov, Kimberly G.
Gerding, Roseanne M.
Reno, Michael J.
Rheault, Tara R.
Rusnak, David W.
Sammond, Douglas M.
Smith, Stephon C.
Uehling, David E.
Waterson, Alex G.
Wood, Edgar R.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (01) : 21 - 26
[36] Design, synthesis and biological evaluation of aryl and hetero-aryl linked thieno[3,2-d]pyrimidine derivatives as anticancer agents
Koteswaraiah, M.
Praveen, Ch
Reddy, Thummaluru Veera
Raveendrareddy, Gopireddy
Srinivas, Uppalanchi
CHEMICAL DATA COLLECTIONS, 2022, 39
[37] Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors
Wang, Ruifeng
Yu, Sijia
Zhao, Xiangxin
Chen, Yixuan
Yang, Bowen
Wu, Tianxiao
Hao, Chenzhou
Zhao, Dongmei
Cheng, Maosheng
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 188
[38] Synthesis and neurotropic activity of 2,4-disubstituted pyrano[4',3':4,5]pyrido[2,3-b]thieno[3,2-d]pyrimidines
Paronikyan, E. G.
Dashyan, Sh. Sh.
Noravyan, A. S.
Dzhagatspanyan, I. A.
Paronikyan, R. G.
Nazaryan, I. M.
Akopyan, A. G.
RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2015, 41 (06) : 663 - 669
[39] Rationalization of the activity Profile of Pyruvate Kinase Isozyme M2 (PKM2) Inhibitors using 3D QSAR
Kusuma, Merugumala
Arora, Sahil
Kalra, Sourav
Chaturvedi, Anuhar
Heuser, Michael
Kumar, Raj
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2021, 21 (25) : 2258 - 2271
[40] Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators
Li, Ridong
Ning, Xianling
Zhou, Shuo
Lin, Zhiqiang
Wu, Xingyu
Chen, Hong
Bai, Xinyu
Wang, Xin
Ge, Zemei
Li, Runtao
Yin, Yuxin
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 143 : 48 - 65

← 1 2 3 4 5 →